

Attorney Docket No.: 5565.214-US





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Woldike et al.

Serial No.: 10/044,426

Group Art Unit: 1636

Examiner: Maria Marvich

RECEIVED AUG 1 4 2002

TECH CENTER 1600/2900

Confirmation No: 3262

Filed: November 13, 2001

For: Method For The Production Of FVII

### **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- Amendment No Fee Transmittal 1.
- Amendment
- Terminal Disclaimer Under 37 C.F.R. 1.321 (in duplicate)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

> Commissioner for Patents Washington, DC 20231


on August 1, 2002.

Carol McFarlane-Fishberg

(name of person mailing paper)

Have Fishberg (signature of person mailing paper)

PATENT TRADEMARK OFFICE





**PATENT** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Woldike et al.

RECEIVED

Serial No.: 10/044,426

Group Art Unit: 1636

AUG 1 4 2002

Filed: November 13, 2001

Examiner: Maria Marvich

TECH CENTER 1600/2900

Confirmation No: 3262

For: Method For The Production Of FVII

# AMENDMENT NO FEE TRANSMITTAL

Commissioner for Patents Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application.

No fee is required for this Amendment. Please charge any additional fee to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447.

Respectfully submitted,

Date: August 1, 2002

Reza Green, Reg. No. 38,475

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123

23650

PATENT TRADEMARK OFFICE



**PATENT** 

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jwoldike et al.

Application No.: 10/044,426

Group Art Unit: 1636

Filed: November 13, 2001

Examiner: M. Marvich

For: Method for the Production of FVII

TECH CENTER 1600/2900

#### **AMENDMENT**

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Office Action mailed May 20; 2002, kindly consider the following remarks.

#### **REMARKS**

Entry of this response is respectfully requested.

Claims 1-5 and 7-10 are pending.

### **Double Patenting**

Claims 1-4 and 7-10 have been rejected under the judicially created doctrine of obvious-type double patenting over claims 1-6 of U.S. Patent No. 6,329,176. The Examiner contends that the present claims represent an obvious variation of the '176 claims.

A terminal disclaimer is appended herewith. It is respectfully submitted on this basis that the rejection has been overcome and may be withdrawn.